Ritter Pharmaceuticals Inc (RTTR) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
Separately, Maxim Group reiterated a buy rating on shares of Ritter Pharmaceuticals in a research note on Tuesday, June 28th.
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded down 3.45% during mid-day trading on Tuesday, hitting $1.40. 1,301 shares of the stock were exchanged. Ritter Pharmaceuticals has a 12 month low of $0.98 and a 12 month high of $3.13. The stock’s 50 day moving average is $1.34 and its 200 day moving average is $1.49. The firm’s market cap is $12.02 million.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. Analysts expect that Ritter Pharmaceuticals will post ($1.38) EPS for the current fiscal year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.